Wegovy vs Zepbound: Long-Term Durability of Response

How Each Drug Works and Why Mechanism Matters for Durability

Both Wegovy and Zepbound reduce body weight by targeting receptors in the hypothalamus and gut, but they activate different receptor combinations. Semaglutide is a selective GLP-1 receptor agonist, while tirzepatide is a dual GIP/GLP-1 receptor agonist. That additional GIP activity appears to amplify fat-mass reduction and may alter the hormonal set-point differently, which has direct implications for how long the effect lasts.

GLP-1 Receptor Agonism (Wegovy)

Semaglutide 2.4 mg mimics endogenous GLP-1, slowing gastric emptying, reducing appetite signaling in the arcuate nucleus, and lowering postprandial glucagon. Weekly subcutaneous injection maintains steady-state plasma concentrations within roughly five to seven days of the first dose at any given titration step. The FDA approved Wegovy in June 2021 for chronic weight management in adults with a BMI of 30 or greater, or BMI of 27 or greater with at least one weight-related comorbidity. fda.gov approval

Dual GIP/GLP-1 Receptor Agonism (Zepbound)

Tirzepatide activates both GIP and GLP-1 receptors with roughly equal affinity. GIP receptor activation may reduce the nausea that limits GLP-1 dose escalation, allowing higher effective doses and potentially greater appetite suppression over time. The FDA approved Zepbound in November 2023 for the same chronic weight-management indication as Wegovy. The dual-mechanism design is the most widely cited explanation for tirzepatide's larger weight-loss numbers, and it may also explain differences in long-run response durability. FDA Zepbound label

Peak Efficacy: What the Key Trials Show

Numbers matter. Neither "about 15 percent" nor "roughly 20 percent" is precise enough when choosing between two drugs.

STEP-1 for Wegovy

In STEP-1 (N=1,961), 68 weeks of subcutaneous semaglutide 2.4 mg once weekly produced a mean weight loss of 14.9% from baseline versus 2.4% with placebo (P<0.001). Roughly 86% of participants achieved at least 5% weight loss, and 50% achieved at least 15% weight loss. Wilding et al., NEJM 2021

Those are strong numbers by any historical standard for a once-weekly injectable. The trial enrolled adults without type 2 diabetes, which is relevant because glycemic burden can modify GLP-1 response.

SURMOUNT-1 for Zepbound

SURMOUNT-1 (N=2,539) ran 72 weeks and found that tirzepatide 15 mg produced 20.9% mean weight loss versus 3.1% placebo (P<0.001). The 10 mg dose produced 19.5% loss and the 5 mg dose 15.0% loss. Jastreboff et al., NEJM 2022

At the highest approved dose, tirzepatide's 20.9% figure exceeds semaglutide's 14.9% by approximately 6 percentage points. In absolute terms, for a 250-pound patient that difference is about 15 pounds.

Indirect Comparison Caution

STEP-1 and SURMOUNT-1 enrolled similar but not identical populations and ran at slightly different durations (68 vs. 72 weeks). Direct cross-trial comparison carries confounding risk. The SURMOUNT-5 trial, which randomizes patients directly between semaglutide 2.4 mg and tirzepatide, is ongoing and has reported preliminary data suggesting tirzepatide superiority, but full peer-reviewed results are not yet available as of mid-2025.

Long-Term Durability: What Happens After the Trial Ends

This is the question most patients actually need answered before starting either drug.

Weight Regain After Stopping Wegovy

The STEP-1 extension (STEP-4, N=803) is the clearest data set. Patients who responded to semaglutide for 20 weeks were re-randomized to continue or switch to placebo. Those who switched to placebo regained approximately two-thirds of their lost weight within 52 weeks. Rubino et al., JAMA 2021

The clinical message is unambiguous. Wegovy is not a finite course. Stopping the drug reverses most of the benefit, and the reversal happens within roughly one year.

Weight Regain After Stopping Zepbound

Comparable data comes from the SURMOUNT-4 trial (N=670). Participants who lost weight on tirzepatide for 36 weeks were re-randomized to continue or switch to placebo. Those who continued tirzepatide lost an additional 5.5% over 52 more weeks. Those who switched to placebo regained about 14 percentage points of the weight they had lost, erasing most of the original reduction. Aronne et al., JAMA 2024

Both drugs, in short, show a similar story: the weight loss is real while you take them and largely reversible when you stop.

On-Therapy Durability at 2 to 4 Years

Neither Wegovy nor Zepbound has yet published randomized, controlled weight-loss data beyond about 2 years in non-diabetic populations. The SELECT trial tracked cardiovascular outcomes with semaglutide 2.4 mg over a median of 34 months (N=17,604) and showed sustained weight loss through that window, which implies on-therapy durability when the drug is continued. Lincoff et al., NEJM 2023

For tirzepatide, the SURMOUNT-MMO cardiovascular outcomes trial is ongoing with results expected by late 2026. Until that data lands, the 72-week SURMOUNT-1 data remains the longest published RCT window.

Tolerability Over Time and Its Effect on Sustained Use

Long-term durability is partly a pharmacology question and partly a tolerability question. Patients who discontinue due to side effects lose all benefit.

Gastrointestinal Side Effects

In STEP-1, nausea was reported by approximately 44% of semaglutide participants versus 16% placebo. Vomiting affected about 24% versus 6%. In SURMOUNT-1, nausea occurred in roughly 31% of the tirzepatide 15 mg group. Vomiting occurred in about 20%. Both drugs caused higher GI event rates during dose escalation, and symptoms typically improved after reaching steady state on a given dose level. Jastreboff et al., NEJM 2022

The slightly lower nausea rate with tirzepatide at maximum dose may contribute to higher completion rates over time, which would translate to better real-world durability. Head-to-head tolerability data from a single trial does not yet exist.

Injection-Site Reactions and Adherence

Both drugs are weekly subcutaneous injections. Pen-device design differs, and patient preference can affect long-term adherence. Neither device has shown meaningful injection-site complication rates in clinical trials.

Switching From Wegovy to Zepbound: What the Evidence Shows

Switching is a common clinical question, and the data here is thin but growing.

The Open-Label Crossover Study

One prospective open-label study (N=52) followed adults who had been on semaglutide 2.4 mg for at least six months with a plateau or inadequate response, then switched them to tirzepatide. At 24 weeks after switching, participants lost an additional mean of 4.5% body weight. No serious adverse events attributable to the switch were reported. This study has not yet been published in a peer-reviewed journal as a full trial but was presented at ObesityWeek 2023 and represents the only prospective switching data available.

HealthRX Clinical Decision Framework: When to Consider Switching

The following framework is used by HealthRX-affiliated clinicians to evaluate candidacy for switching from Wegovy to Zepbound. It is not a substitute for individual clinical judgment.

Switch is reasonable when ALL of these apply:

1. Patient has been on maximum tolerated Wegovy dose (2.4 mg weekly) for at least 12 weeks.
2. Weight loss plateau defined as less than 1% body weight change over 8 consecutive weeks.
3. No contraindication to tirzepatide (personal or family history of MEN2 or medullary thyroid carcinoma applies equally to both drugs; pancreatitis history warrants caution with both).
4. Patient can tolerate a new titration schedule (tirzepatide is typically started at 2.5 mg weekly regardless of prior GLP-1 dose).

Continue Wegovy when:

• Patient is still losing at any dose below 2.4 mg (still in active trajectory).
• Side effects on Wegovy are controlled and the patient prefers not to restart a titration sequence.
• Cardiovascular risk reduction is the primary goal and SELECT data (N=17,604, median 34 months) is the most relevant evidence for the patient's profile.

Titration Protocol When Switching

Clinicians should generally start tirzepatide at 2.5 mg weekly regardless of the patient's prior semaglutide dose. The GIP receptor activation produces a qualitatively different physiological response, and prior GLP-1 tolerance does not reliably predict tirzepatide tolerability at higher doses. The standard Zepbound titration schedule increases the dose by 2.5 mg every four weeks as tolerated, targeting 10 mg or 15 mg as the maintenance dose. Zepbound prescribing information

Cardiovascular Outcomes: A Key Durability Differentiator

Sustained cardiovascular benefit may matter as much as sustained weight loss for many patients.

SELECT Trial Data for Wegovy

The SELECT trial randomized 17,604 adults with established cardiovascular disease but without diabetes to semaglutide 2.4 mg or placebo. Over a median 34 months, the semaglutide group had a 20% relative risk reduction in the composite MACE endpoint (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke). Lincoff et al., NEJM 2023

The FDA subsequently approved Wegovy for cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight in March 2024. Zepbound does not yet carry this label.

As stated in the SELECT trial publication: "Semaglutide at a dose of 2.4 mg per week led to a significantly lower incidence of cardiovascular events than placebo among patients with preexisting cardiovascular disease and overweight or obesity."

SURMOUNT-MMO for Zepbound

The tirzepatide cardiovascular outcomes trial is ongoing. Until results publish, Zepbound lacks the label indication and trial-level evidence for cardiovascular risk reduction that Wegovy now carries. For a patient whose primary driver is cardiovascular risk, Wegovy has a meaningful evidence advantage as of mid-2025.

Real-World Durability: Insurance, Supply, and Adherence Factors

Clinical trial durability numbers assume consistent drug supply and adherence. Real-world durability is lower.

Medication Adherence Rates

A 2023 analysis using a large U.S. Pharmacy claims database found that approximately 44% of patients who filled a first prescription for semaglutide had discontinued by 12 months, and only about 33% remained on therapy at 24 months. Rates for tirzepatide at 12 months were similar based on limited early claims data. Wharton et al., Obesity 2023

Those numbers mean that real-world durability is substantially worse than trial durability. Structured follow-up, behavioral support, and coverage stability all correlate with continued adherence.

Insurance Coverage and Cost

Wegovy's cardiovascular label may improve insurance coverage for patients with documented cardiovascular disease. Zepbound competes on rebate contracts and has a lower list price per unit dose than Wegovy in many pharmacy benefit structures. Drug cost is a primary driver of real-world discontinuation and should be addressed at the time of prescribing.

Side-by-Side Summary Table

| Feature | Wegovy (semaglutide 2.4 mg) | Zepbound (tirzepatide 15 mg) | |---|---|---| | Mechanism | GLP-1 receptor agonist | GIP/GLP-1 dual agonist | | Peak trial weight loss | 14.9% (STEP-1, 68 wk) | 20.9% (SURMOUNT-1, 72 wk) | | Weight regain off-drug | ~2/3 within 52 wk (STEP-4) | ~14 pp within 52 wk (SURMOUNT-4) | | CV outcomes label | Yes (SELECT, March 2024) | No (SURMOUNT-MMO pending) | | Approved indication | Chronic weight management, CV risk reduction | Chronic weight management | | Nausea rate at max dose | ~44% (STEP-1) | ~31% (SURMOUNT-1) | | Dosing | 2.4 mg SC weekly | 10 or 15 mg SC weekly | | Switching data | Reference drug | ~4.5% additional loss after crossover |

Who Is the Better Candidate for Each Drug

Not every patient has the same goal or risk profile. Mechanistic differences translate to different best-fit patient types.

Patients Who May Do Better on Wegovy

• Adults with established cardiovascular disease who want both weight loss and a labeled CV risk reduction indication.
• Patients with prior bariatric surgery who prefer a single-mechanism GLP-1 agent with the longest post-market safety record in obesity.
• Patients enrolled in trials or clinical programs where consistent longitudinal data on semaglutide is needed.

Patients Who May Do Better on Zepbound

• Adults without CV disease who want the largest possible weight reduction from a single drug.
• Patients who stopped semaglutide due to persistent nausea (GIP co-agonism may reduce GI burden at comparable doses).
• Patients who reached a plateau on maximum-dose Wegovy after at least 12 weeks and want a second-line escalation within the injectable class.